Weight Loss Meds Solves Unexpected Problem
New research suggests that advanced weight-loss medications like Ozempic and Wegovy may significantly reduce alcohol consumption in a relatively short period. A study recently published in Diabetes, Obesity and Metabolism found that individuals using semaglutide or liraglutide—both medications in the GLP-1 receptor agonist class—reduced their alcohol intake by approximately two-thirds over the course of four months.
These medications work by mimicking a naturally occurring hormone called GLP-1, which plays a role in regulating blood sugar, insulin levels, appetite, and digestion. According to Dr. Carel le Roux of University College Dublin, these drugs may also influence brain circuits related to cravings, potentially reducing the urge to consume alcohol as well as food. Le Roux explained that many patients describe the process of cutting back on alcohol while using these drugs as “effortless,” suggesting a direct neurological effect.
The study followed 262 adults who were either overweight or obese and receiving treatment at a Dublin clinic. All participants were prescribed semaglutide or liraglutide for weight management. Among the group, 68% were regular alcohol consumers, and this subset saw a notable 68% decrease in alcohol use within four months. The researchers noted that this reduction is similar to what is achieved with nalmefene, a medication used in Europe to treat alcohol dependency.
While the results are promising, the study did have limitations. It involved a relatively small group and lacked a control group for comparison. Despite these constraints, the findings were compelling enough to be presented at a recent meeting of the European Association for the Study of Obesity in Malaga, Spain.
Experts believe this emerging evidence highlights the potential for GLP-1-based medications to offer benefits beyond weight loss, particularly in helping to curb addictive behaviors like alcohol consumption. Further research is needed, but the study adds to growing interest in the broader applications of these treatments.
Discussion about this post